- Home
- MTEK vs SNGX Comparison
MTEK vs SNGX Comparison
Compare MTEK & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- SNGX
- Stock Information
- Founded
- MTEK 2008
- SNGX 1987
- Country
- MTEK Israel
- SNGX United States
- Employees
- MTEK N/A
- SNGX N/A
- Industry
- MTEK
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MTEK
- SNGX Health Care
- Exchange
- MTEK Nasdaq
- SNGX Nasdaq
- Market Cap
- MTEK 15.1M
- SNGX 13.8M
- IPO Year
- MTEK 2022
- SNGX 1987
- Fundamental
- Price
- MTEK $1.42
- SNGX $1.47
- Analyst Decision
- MTEK
- SNGX Strong Buy
- Analyst Count
- MTEK 0
- SNGX 1
- Target Price
- MTEK N/A
- SNGX $6.00
- AVG Volume (30 Days)
- MTEK 128.5K
- SNGX 267.9K
- Earning Date
- MTEK 09-26-2025
- SNGX 11-07-2025
- Dividend Yield
- MTEK N/A
- SNGX N/A
- EPS Growth
- MTEK N/A
- SNGX N/A
- EPS
- MTEK N/A
- SNGX N/A
- Revenue
- MTEK $3,375,716.00
- SNGX N/A
- Revenue This Year
- MTEK N/A
- SNGX N/A
- Revenue Next Year
- MTEK N/A
- SNGX N/A
- P/E Ratio
- MTEK N/A
- SNGX N/A
- Revenue Growth
- MTEK N/A
- SNGX N/A
- 52 Week Low
- MTEK $1.03
- SNGX $1.09
- 52 Week High
- MTEK $6.47
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- MTEK 47.86
- SNGX 50.09
- Support Level
- MTEK $1.03
- SNGX $1.25
- Resistance Level
- MTEK $1.39
- SNGX $1.53
- Average True Range (ATR)
- MTEK 0.13
- SNGX 0.11
- MACD
- MTEK 0.05
- SNGX 0.03
- Stochastic Oscillator
- MTEK 60.78
- SNGX 80.00
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).